News

Prexton is a biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions. Forbion and Seroba Life Sciences (IE) co-led the financing round,

The letter, titled US immigration order strikes against biotech, was published in Nature Biotechnology. Some of the big pharma companies on the list include Biogen, Alnylam Pharmaceuticals, Seattle

The watchdog filed a complaint in the US District Court for the District of Delaware. It wants the court to prohibit the pharma from submitting repetitive and baseless filings with

Acticor Biotech had already secured €1,4M in the first closing, which brings the total amount invested to €2,9M. This new fund will enable Acticor Biotech to pursue the

GBM is a particularly aggressive brain tumor, with a poor prognosis. GW has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European

Perrigo has notified Valeant Pharmaceuticals North America LLC and Dow Pharmaceutical Sciences, Inc. (Valeant) the owner of both the New Drug Application and patents listed in FDA's Orange

The company claims that Parsabiv is the first new therapy approved for the condition in 12 years. It is designed to be administered intravenously three times per week

The company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA). Ariad’s US marketing application is currently under the US Food and Drug Administration

The addition of Vault Submissions Publishing unifies publishing capabilities and enterprise content management to streamline end-to-end submission development. Now life sciences companies can plan, review, publish, archive, and